SEC Form 4 · accession 0001209191-17-004978
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Jennifer J Rhodes
Officer — CBO, GC & Compliance Officer
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 18, 2017 | A | 11,250 | $0.00 | A | 27,187 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $16.61 | Jan 18, 2017 | A | 67,500 | A | — | Jan 17, 2027 | Common Stock | 67,500 | 67,500 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest 1/4th on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021.
- F2The shares subject to the option shall become vested according to the following schedule: 1/48th of the shares subject to the option shall vest monthly beginning on February 1, 2017 for 48 months.